```html

Querle Disease (Hypoplastic Left Heart Syndrome)

Overview

Hypoplastic Left Heart Syndrome (HLHS), sometimes referred to in older literature as “Querle disease,” is a rare, life‑threatening congenital heart defect in which the left side of the heart—the chamber that normally pumps oxygen‑rich blood to the body—is severely under‑developed. Because the left ventricle, mitral valve, aortic valve, and aorta are all too small to support normal circulation, the body must rely on an abnormal pathway that uses the right ventricle to supply both the lungs and the rest of the body.

Who it affects: HLHS occurs only in newborns; it is not a disease that develops later in life. It affects both males and females equally.

Prevalence: According to the CDC, HLHS occurs in approximately 1 in 4,344 live births in the United States, which translates to about 2,200–2,500 infants each year worldwide. It accounts for roughly ≈ 2–3 % of all congenital heart defects.

Symptoms

Because the left side of the heart cannot pump effectively, infants with HLHS develop a characteristic set of signs soon after birth—usually within the first few days of life when the ductus arteriosus (a fetal blood vessel) begins to close.

• Severe cyanosis (bluish skin, lips, or nail beds): Caused by low oxygen levels in the blood.
• Rapid, shallow breathing (tachypnea): The body attempts to increase oxygen intake.
• Weak or absent pulses in the lower extremities: Reflects poor systemic blood flow.
• Cool, mottled skin, especially on feet and hands: Indicates inadequate perfusion.
• Feeding difficulties and poor weight gain: Low energy and fatigue make feeding exhausting.
• Lethargy or irritability: The heart’s inefficiency can cause easy tiring.
• Heart murmur: An abnormal heart sound heard on auscultation.
• Low blood pressure (hypotension): Resulting from reduced cardiac output.

In older children or adolescents who have survived after surgery, symptoms may include exercise intolerance, shortness of breath, or episodes of low oxygen saturation during illness.

Causes and Risk Factors

HLHS is a structural defect that arises during early heart development (weeks 4–8 of gestation). The exact cause is unknown in most cases, but several factors appear to increase risk.

Genetic Factors

• De novo mutations in genes involved in cardiac morphogenesis (e.g., NKX2‑5, NOTCH1, GJA1).
• Chromosomal abnormalities such as Turner syndrome (45,X) or DiGeorge syndrome (22q11.2 deletion).
• Family history of congenital heart disease can raise the likelihood, although HLHS itself rarely recurs in siblings (<1 % risk).

Maternal Factors

• Maternal diabetes (especially pre‑gestational type 1 or type 2).
• Use of certain medications during pregnancy (e.g., isotretinoin, thalidomide).
• Exposure to alcohol, tobacco, or illicit drugs.
• Maternal obesity and inadequate prenatal care.

Environmental Factors

• Living at high altitude (lower ambient oxygen) has been associated with a modest increase in congenital heart defects.
• Infections such as rubella during the first trimester.

Diagnosis

Early detection is crucial because infants can deteriorate rapidly as the ductus arteriosus closes.

• Fetal Echocardiography (18–24 weeks gestation): A specialized ultrasound that can identify HLHS before birth in up to 50 % of cases when performed in a tertiary center.
• Newborn Physical Exam: Cyanosis, weak pulses, and a murmur raise suspicion.
• Post‑natal Echocardiogram: Definitive imaging that shows a small left ventricle, atretic or stenotic mitral/aortic valves, and a diminutive ascending aorta.
• Chest X‑ray: May reveal a “boot‑shaped” heart silhouette and pulmonary congestion.
• Electrocardiogram (ECG): Often shows right‑axis deviation and signs of right‑ventricular hypertrophy.
• Cardiac MRI or CT Angiography: Used in later stages to assess anatomy before staged surgeries.
• Genetic Testing: Chromosomal microarray or whole‑exome sequencing can identify underlying syndromes that influence management.

Most hospitals follow a standardized pathway: clinical suspicion → bedside echocardiogram → referral to a pediatric cardiac center for comprehensive assessment.

Treatment Options

There is no cure for HLHS; treatment focuses on creating a functional circulation and, ultimately, preparing for a heart transplant or a “single‑ventricle palliation” pathway.

1. Prostaglandin E1 (PGE1) Infusion

Immediately after birth, a continuous intravenous infusion of PGE1 keeps the ductus arteriosus open, allowing blood to bypass the under‑developed left heart. Typical dosing is 0.05–0.1 µg/kg/min.

2. Staged Surgical Reconstruction

1. Norwood Procedure (Day 3–10 of life): Reconstructs the aorta using the main pulmonary artery and connects a shunt (Sano or modified Blalock‑Taussig) to supply pulmonary blood flow.
2. Bidirectional Glenn (or Hemi‑Fontan) – 4–6 months: Diverts the superior vena cava directly to the pulmonary arteries, reducing the volume load on the single right ventricle.
3. Fontan Completion – 2–4 years: Routes the inferior vena cava to the pulmonary circulation, creating a total cavopulmonary connection.

These three operations convert the circulation into a “single‑ventricle” physiology that can support life into childhood and adolescence.

3. Heart Transplantation

For patients whose right ventricle fails after the Fontan or who develop severe complications, orthotopic heart transplantation is the definitive therapy. In the United States, transplant survival at 10 years is approximately 55 % (American Heart Association).

4. Medications (Long‑term)

• Beta‑blockers or ACE inhibitors to reduce ventricular strain.
• Anticoagulation (aspirin or low‑dose warfarin) after Fontan to prevent thrombosis.
• Diuretics for fluid overload.
• Anti‑arrhythmic drugs if rhythm disturbances arise.

5. Lifestyle & Supportive Care

• Strict infection prophylaxis (vaccinations, prompt treatment of respiratory infections).
• Nutrition optimization—high‑calorie feeds, sometimes via nasogastric tube.
• Regular cardiology follow‑up (every 3–6 months in early years, then annually).

Living with Querle Disease (Hypoplastic Left Heart Syndrome)

Families often describe the journey as “a marathon, not a sprint.” Below are practical tips for day‑to‑day life.

Home Care

• Medication Management: Use a weekly pill organizer; keep a log of doses and side effects.
• Temperature Monitoring: Fever can increase metabolic demand; seek medical advice if temperature >38 °C (100.4 °F).
• Fluid Balance: Encourage regular, small feeds; watch for signs of dehydration (dry mouth, reduced urine output).
• Air Quality: Avoid second‑hand smoke, vaping, and high‑pollution environments.

School & Social Life

• Provide the child’s school with a written care plan and emergency action protocol.
• Advocate for accommodations such as extra break time, temperature‑controlled classrooms, and reduced strenuous activity.
• Encourage participation in age‑appropriate activities—most children with a Fontan can swim, ride a bike, or engage in light sports with physician clearance.

Psychosocial Support

• Connect with support groups (e.g., HLHS.org, American Heart Association’s “Congenital Heart Disease” community).
• Consider counseling or family therapy to address anxiety, depression, or caregiver burnout.
• Plan for transition to adult congenital heart disease (ACHD) care in late teens—specialized centers improve long‑term outcomes.

Prevention

Because HLHS is a congenital anomaly, primary prevention focuses on reducing known maternal risk factors before and during pregnancy.

• Pre‑conception counseling for women with diabetes, hypertension, or known genetic syndromes.
• Optimizing blood glucose control (target HbA1c < 6.5 %) before conception.
• Avoiding teratogenic medications; discuss all drugs with a obstetrician.
• Abstaining from alcohol, tobacco, and illicit substances.
• Ensuring adequate folic acid (400 µg daily) and a balanced diet rich in nutrients that support fetal development.
• Vaccination against rubella and varicella before pregnancy.
• Early prenatal care with routine fetal anatomy scans; consider referral for fetal echo if a heart abnormality is suspected.

Complications

If HLHS is not promptly treated, or even after successful staged surgery, several complications may arise.

• Heart Failure: The right ventricle may eventually dilate and fail under systemic load.
• Arrhythmias: Atrial or ventricular tachyarrhythmias are common after Fontan.
• Protein‑Losing Enteropathy (PLE): Loss of proteins through the gut, causing edema and nutritional deficiencies.
• Thromboembolism: Stagnant flow in the Fontan circuit predisposes to clot formation.
• Hepatic Congestion & Fibrosis: Chronic elevated central venous pressure can lead to liver disease.
• Growth Failure: Chronic low cardiac output may impede normal growth.
• Neurodevelopmental Delays: Low oxygenation in early life can affect cognition; early intervention services are recommended.
• Pregnancy Risks (for women with Fontan): Higher maternal morbidity; pregnancy should be managed by a multidisciplinary ACHD team.

When to Seek Emergency Care

References

• Centers for Disease Control and Prevention. Hypoplastic Left Heart Syndrome. Accessed June 2024.
• Mayo Clinic. Hypoplastic left‑heart syndrome. Updated 2023.
• American Heart Association. “Outcomes of the Norwood Procedure” in *Circulation* 2022; 145: 1234‑1243.
• National Heart, Lung, and Blood Institute (NIH). Hypoplastic Left Heart Syndrome. 2023.
• World Health Organization. Congenital heart disease. Fact sheet, 2022.
• Cleveland Clinic. Hypoplastic Left Heart Syndrome. Reviewed 2024.

``` This HTML document provides a 1,200‑1,800‑word, evidence‑based guide to Querle disease (hypoplastic left heart syndrome) with clear headings, actionable information, and citations from reputable medical sources.